CLEVELAND--(BUSINESS WIRE)--Arteriocyte, Inc., a clinical stage research and development company focused on creating stem cell therapies for the treatment of vascular diseases, announced today that it has reached the three month patient follow-up point for its SEACOAST Phase I clinical trial. The study is evaluating the safety of ACY001, Arteriocyte’s lead cellular therapy product. ACY001 is an adult stem cell therapy harvested from bone marrow to treat chronic ischemia, a serious form of heart disease.
